Alzamend Neuro Inc SEC Filings

Alzamend Neuro, Inc. reported cash of $5,928,830 at July 31, 2025, up from $4,177,377 at April 30, 2025, and a net increase in cash of $1,672,214 for the period. The company recorded a net loss of $2.7 million for the three months ended July 31, 2025, and used $2.4 million in operating activities during the quarter. Management states the company expects to continue to incur net losses in the foreseeable future. As of the filing the company reported working capital of $4.9 million, an accumulated deficit of $61.2 million, and stockholders' equity of $5.3 million. The filing discloses that the company has historically financed operations primarily through issuances of equity and debt and details multiple preferred and common equity transactions and conversions completed during the period.

Alzamend Neuro (ALZN) – Schedule 13D/A Amendment No. 6 (filed 08/01/25)

The filing consolidates current beneficial ownership of Milton C. Ault III and eight related reporting persons. Collectively, Mr. Ault, Hyperscale Data (f/k/a Ault Alliance), Ault Lending and affiliated life-sciences entities report 706,321 common shares—about 18.5 % of ALZN’s 3,139,861 shares outstanding as of 07/30/25. The position comprises:

• 8,260 common shares and 23,334 warrant-covered shares held by Ault Lending
• 661,743 shares issuable upon conversion of Series B Convertible Preferred Stock held by Ault Lending
• 12 warrant-covered shares held by Hyperscale Data
• 11,068 shares held by Ault Life Sciences and 61 shares held by Ault Life Sciences Fund
• 1,843 shares held directly by Mr. Ault

Hyperscale Data indirectly controls Ault Lending and therefore shares voting/dispositive power over 693,349 shares (18.1 %). Other insiders—William B. Horne, Henry C.W. Nisser, Kenneth S. Cragun and David J. Katzoff—each hold <0.1 % via small share and option positions. No reporting person has been convicted of, or sanctioned for, securities violations within the last five years, and no new transactions occurred in the past 60 days. Aside from the updated ownership table and principal-occupation details, prior disclosures remain unchanged.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.

Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.

The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.

Alzamend Neuro, Inc. (ALZN) has filed an amended Form 144 (Form 144/A) disclosing the intent of an undisclosed shareholder to sell 939,281 shares of common stock through broker E*TRADE Financial on or about 14 July 2025 on the NASDAQ exchange. The filing lists an aggregate market value of US $3,005,699.20 for the proposed sale. For context, the company reports 2,896,432 shares outstanding, meaning the planned disposition represents roughly one-third of the free-trading equity base, a size that can materially influence trading liquidity and share-price dynamics.

The notice also details the historical acquisition of the securities: purchases span private placements, IPO participation, open-market buys, warrant exercises and a sizable 905,172-share commitment tied to Series B convertible preferred stock, plus 25,804 shares available via warrants. Although these convertible and warrant positions are not part of the current sale, their disclosure signals additional potential share supply.

Within the past three months the same party (identified in the filing as Ault Lending, LLC) sold 1,213 shares for gross proceeds of $6,138. No material adverse information is represented, and the seller certifies compliance with Rule 144.

Key takeaways for investors: (1) the block size is large relative to the float, introducing a possible overhang; (2) the transaction is a secondary sale—no new capital accrues to the company; (3) additional convertible and warrant holdings could expand the float further if exercised or converted. The filing is procedural, but the magnitude of the proposed sale makes it noteworthy for liquidity and near-term price action.